Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study.

Pan S, Tsakok T, Wei R, Dand N, Loeff FC, Bloem K, de Vries A, Baudry D, Duckworth M, Pushpa-Rajah A, Russell A, Alsharqi A, Becher G, Murphy R, Wahie S, Wright A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, Burden AD, Rispens T, Mahil SK, Standing JF, Smith CH, BADBIR Study Group, BSTOP Study Group and the PSORT Consortium

Open source

DOI: 10.1111/cts.70563
Published: 2026 May
Container: Clinical and translational science
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/cts.70563,
  title = {Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study.},
  author = {Pan S and Tsakok T and Wei R and Dand N and Loeff FC and Bloem K and de Vries A and Baudry D and Duckworth M and Pushpa-Rajah A and Russell A and Alsharqi A and Becher G and Murphy R and Wahie S and Wright A and Griffiths CEM and Reynolds NJ and Barker J and Warren RB and Burden AD and Rispens T and Mahil SK and Standing JF and Smith CH and BADBIR Study Group and BSTOP Study Group and the PSORT Consortium},
  year = {2026},
  journal = {Clinical and translational science},
  doi = {10.1111/cts.70563},
  url = {https://doi.org/10.1111/cts.70563}
}

RIS

TY  - JOUR
TI  - Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study.
AU  - Pan S
AU  - Tsakok T
AU  - Wei R
AU  - Dand N
AU  - Loeff FC
AU  - Bloem K
AU  - de Vries A
AU  - Baudry D
AU  - Duckworth M
AU  - Pushpa-Rajah A
AU  - Russell A
AU  - Alsharqi A
AU  - Becher G
AU  - Murphy R
AU  - Wahie S
AU  - Wright A
AU  - Griffiths CEM
AU  - Reynolds NJ
AU  - Barker J
AU  - Warren RB
AU  - Burden AD
AU  - Rispens T
AU  - Mahil SK
AU  - Standing JF
AU  - Smith CH
AU  - BADBIR Study Group
AU  - BSTOP Study Group and the PSORT Consortium
PY  - 2026
JO  - Clinical and translational science
DO  - 10.1111/cts.70563
UR  - https://doi.org/10.1111/cts.70563
ER  -

APA

S, P., T, T., R, W., N, D., FC, L., K, B., A, D. V., D, B., M, D., A, P., A, R., A, A., G, B., R, M., S, W., A, W., CEM, G., NJ, R., J, B., RB, W., AD, B., T, R., SK, M., JF, S., CH, S., Group, B. S., & Consortium, B. S. G. A. T. P. (2026). Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study.. Clinical and translational science. https://doi.org/10.1111/cts.70563

Source records

pubmed · retrieved 2026-09-26T22:28:42.241Z